BRISBANE, Calif. — May 5, 2026 — Leads & Copy — Pacira BioSciences, Inc. (Nasdaq: PCRX) announced it has mailed a letter to stockholders regarding the company’s 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026.
The letter highlights Pacira’s successful execution of its 5×30 strategy, which has driven the company’s stock up over 30% since its launch. First quarter 2026 results indicate the company is on the right strategic path with strong commercial execution and demand trends across the portfolio.
The company is urging stockholders to vote “FOR” Pacira’s three board nominees: Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans.
According to the letter, Pacira’s CEO, Frank D. Lee, established the 5×30 strategy in January 2025. The five-pillar plan aims to reinvigorate growth and balance the revenue portfolio by 2030, focusing on patients served, product revenue, profitability, pipeline development, and partnerships.
In 2025, Pacira treated over 2.5 million patients and is on track to reach 3 million annually by 2030, driven by the NOPAIN Act and indication expansion. A recent survey indicated 92% of physicians and pharmacy leaders believe NOPAIN is contributing to reductions in opioid prescribing. Pacira has expanded commercial coverage, securing reimbursement outside the bundle for 110 million lives across commercial and government plans.
Topline results from a Phase 3 study of ZILRETTA in shoulder osteoarthritis (OA) and a registrational study of iovera° as a treatment for spasticity are expected before the end of 2026.
EXPAREL’s growth is attributed to enhanced intellectual property protection, greater long-term visibility due to a settlement in April 2025, and expanded commercial reach through partnerships, including agreements with LG Chem and Johnson & Johnson MedTech.
The company reported record-high GAAP and non-GAAP gross margins in 2025 and is focused on manufacturing process improvements. It is also advancing an innovative clinical-stage pipeline with Phase 2 clinical programs.
PCRX-201, a gene therapy for OA, showed positive results in a Phase 1 study, with over 70% of patients experiencing a 50% or greater improvement in pain and stiffness. PCRX-2002, a local analgesic for postsurgical pain in-licensed from AmacaThera, Inc. in November 2025, demonstrated sustained release of ropivacaine through 14 days in a Phase 1 study.
Pacira signed a co-promotion agreement with Johnson & Johnson MedTech for ZILRETTA and a licensing and distribution agreement with LG Chem for EXPAREL in select Asia-Pacific markets.
In the first quarter of 2026, Pacira achieved $177 million in revenue, a 5% increase from the prior year period, and reported Adjusted EBITDA of $40.2 million. The company executed $50 million in share repurchases in the first quarter, retiring approximately 2.2 million shares of common stock.
The company is cautioning stockholders against allowing DOMA’s nominees to join the Pacira board. Pacira says DOMA has not articulated a clear plan to drive stockholder value.
According to Pacira, DOMA’s plan is to downgrade the Pacira board with three unqualified director candidates who do not have any public board experience, implement broad cost cuts without regard to the impact on revenue growth, discontinue pipeline development, replace our CEO only a little more than one year after announcing 5×30 and engage bankers to proceed with an immediate sale process of the Company.
D.F. King & Co., Inc. is acting as Pacira’s proxy solicitor. Goldman Sachs & Co. LLC is acting as financial advisor and Perkins Coie LLP is acting as legal counsel to Pacira.
Pacira delivers non-opioid pain therapies, including EXPAREL, ZILRETTA, and iovera°. The company is also advancing PCRX-201 for osteoarthritis of the knee.
Source: Pacira BioSciences, Inc.
